Annuncio pubblicitario
Italia markets open in 2 hours 40 minutes

  • Dow Jones

    39.671,04
    -201,95 (-0,51%)
     

  • Nasdaq

    16.801,54
    -31,08 (-0,18%)
     

  • Nikkei 225

    39.088,47
    +471,37 (+1,22%)
     

  • EUR/USD

    1,0834
    +0,0007 (+0,07%)
     

  • Bitcoin EUR

    64.093,23
    -392,03 (-0,61%)
     

  • CMC Crypto 200

    1.512,50
    -13,92 (-0,91%)
     

  • HANG SENG

    18.930,02
    -265,58 (-1,38%)
     

  • S&P 500

    5.307,01
    -14,40 (-0,27%)
     

Clearside Biomedical to Participate in a Panel Discussion at the JonesTrading 2023 Healthcare Summit

Clearside Biomedical, Inc.
·1 minuto per la lettura
Clearside Biomedical, Inc.
Clearside Biomedical, Inc.

ALPHARETTA, Ga., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Charles A. Deignan, Chief Financial Officer, will participate in a panel discussion at the JonesTrading 2023 Healthcare Summit. The panel, entitled, All About Eyes: Paradigm Shifting Therapeutic Innovations in Ophthalmology will take place on October 10, 2023 at 2:00 p.m. ET.

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). Clearside’s SCS injection platform, utilizing the Company’s patented SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company’s lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. Clearside developed and gained approval for its first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit clearsidebio.com.

Investor and Media Contacts:

Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206

Source: Clearside Biomedical, Inc.